Monte Rosa Therapeutics and Novartis have agreed a global license agreement to advance VAV1 molecular glue degrader-based medicines (MGDs). The deal includes MRT-6160, which is currently in an ongoing Phase I study for immune-mediated conditions. Under the terms of the agreement, Novartis will obtain exclusive worldwide rights to develop, manufacture and commercialise MRT-6160 and other […]

To read this content in full, you need to login.

Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!